KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBITDA: 2017-2025

Historic EBITDA for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$260.0 million.

  • Moderna's EBITDA fell 271.43% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 28.59%. This contributed to the annual value of -$3.9 billion for FY2024, which is 6.94% up from last year.
  • Moderna's EBITDA amounted to -$260.0 million in Q3 2025, which was up 71.33% from -$907.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's EBITDA ranged from a high of $5.4 billion in Q4 2021 and a low of -$2.0 billion during Q3 2023.
  • For the 3-year period, Moderna's EBITDA averaged around -$945.5 million, with its median value being -$1.1 billion (2025).
  • As far as peak fluctuations go, Moderna's EBITDA surged by 2,609.84% in 2021, and later slumped by 20,866.67% in 2024.
  • Quarterly analysis of 5 years shows Moderna's EBITDA stood at $5.4 billion in 2021, then tumbled by 70.79% to $1.6 billion in 2022, then slumped by 99.62% to $6.0 million in 2023, then crashed by 20,866.67% to -$1.2 billion in 2024, then tumbled by 271.43% to -$260.0 million in 2025.
  • Its EBITDA stands at -$260.0 million for Q3 2025, versus -$907.0 million for Q2 2025 and -$1.1 billion for Q1 2025.